| Literature DB >> 32864893 |
Jesus Paez-Mayorga1,2, Simone Capuani1, Marco Farina1,3, Maria Luisa Lotito1,4, Jean A Niles5, Hector F Salazar1, Jessica Rhudy1, Lucas Esnaola1, Corrine Ying Xuan Chua1, Francesca Taraballi6,7, Bruna Corradetti1,8, Kathryn A Shelton9, Pramod N Nehete9,10, Joan E Nichols5, Alessandro Grattoni1,11,12.
Abstract
The current standard for cell encapsulation platforms is enveloping cells in semipermeable membranes that physically isolate transplanted cells from the host while allowing for oxygen and nutrient diffusion. However, long-term viability and function of encapsulated cells are compromised by insufficient oxygen and nutrient supply to the graft. To address this need, a strategy to achieve enhanced vascularization of a 3D-printed, polymeric cell encapsulation platform using platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs) is investigated. The study is conducted in rats and, for clinical translation relevance, in nonhuman primates (NHP). Devices filled with PRP, MSCs, or vehicle hydrogel are subcutaneously implanted in rats and NHP and the amount and maturity of penetrating blood vessels assessed via histopathological analysis. In rats, MSCs drive the strongest angiogenic response at early time points, with the highest vessel density and endothelial nitric oxide synthase (eNOS) expression. In NHP, PRP and MSCs result in similar vessel densities but incorporation of PRP ensues higher levels of eNOS expression. Overall, enrichment with PRP and MSCs yields extensive, mature vascularization of subcutaneous cell encapsulation devices. It is postulated that the individual properties of PRP and MSCs can be leveraged in a synergistic approach for maximal vascularization of cell encapsulation platforms.Entities:
Keywords: cell encapsulation; cell transplantation; mesenchymal stem cells; subcutaneous implants; vascularization
Mesh:
Substances:
Year: 2020 PMID: 32864893 DOI: 10.1002/adhm.202000670
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933